BioStock: Big investment sign of great interest in mitochondrial diseases

A number of major deals in treatments within the field of mitochondrial diseases speaks of a growing interest for the area from the pharmaceutical industry. Last week saw another sign of this when Reneo Pharmaceuticals announced that a consortium led by Novo Ventures and Abingworth is entering the company with an investment of 95 MUSD. One Swedish company active in the field of mitochondrial diseases is Lund-based Abliva that is currently preparing for a phase II/III study with its main candidate KL1333 in the second half of 2021.

 Read the full article at biostock.se:

https://www.biostock.se/en/big-investment-sign-of-great-interest-in-mitochondrial-diseases/
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se